Pub Date : 2020-12-25DOI: 10.30683/1929-2279.2020.09.01
Zhi Shi
{"title":"A HPLC-UV Method for the Quantification of Regorafenib in Tumor","authors":"Zhi Shi","doi":"10.30683/1929-2279.2020.09.01","DOIUrl":"https://doi.org/10.30683/1929-2279.2020.09.01","url":null,"abstract":"","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46566867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-25DOI: 10.30683/1929-2279.2020.09.04
Jun Jiang
: There is no standard treatment for locally advanced cervical cancer, patients with residual tumor after radical concurrent chemoradiotherapy. This study was to investigate the short-term efficacy and safety of the targeted drug apatinib mesylate in patients with tumor residual after radical chemoradiotherapy for locally advanced cervical cancer. Eight patients with residual tumors after localized concurrent chemoradiotherapy with locally advanced cervical cancer were treated with apatinib (250 mg once daily, orally). The short-term efficacy and safety of the eight patients treated with apatinib were initially evaluated. Total Effectiveness (ORR) 37.5% and disease control rate (DCR) 100.0%. The toxicity and side effects were light, mainly manifested as 37.5% of hand-foot syndrome, 37.5% of proteinuria, 25.0% of hypertension, 12.5% of fatigue, 12.5% of rash, and 12.5% of vomiting. No serious toxic side effects associated with the drug were observed. Apatinib mesylate can be safely used in patients with residual tumor after radical chemoradiotherapy for locally advanced cervical cancer. The short-term effect is positive and the side effects are low.
{"title":"Clinical Analysis of Apatinib in the Treatment of Patients with Residual Tumor after Radical Chemoradiotherapy for Locally Advanced Cervical Cancer","authors":"Jun Jiang","doi":"10.30683/1929-2279.2020.09.04","DOIUrl":"https://doi.org/10.30683/1929-2279.2020.09.04","url":null,"abstract":": There is no standard treatment for locally advanced cervical cancer, patients with residual tumor after radical concurrent chemoradiotherapy. This study was to investigate the short-term efficacy and safety of the targeted drug apatinib mesylate in patients with tumor residual after radical chemoradiotherapy for locally advanced cervical cancer. Eight patients with residual tumors after localized concurrent chemoradiotherapy with locally advanced cervical cancer were treated with apatinib (250 mg once daily, orally). The short-term efficacy and safety of the eight patients treated with apatinib were initially evaluated. Total Effectiveness (ORR) 37.5% and disease control rate (DCR) 100.0%. The toxicity and side effects were light, mainly manifested as 37.5% of hand-foot syndrome, 37.5% of proteinuria, 25.0% of hypertension, 12.5% of fatigue, 12.5% of rash, and 12.5% of vomiting. No serious toxic side effects associated with the drug were observed. Apatinib mesylate can be safely used in patients with residual tumor after radical chemoradiotherapy for locally advanced cervical cancer. The short-term effect is positive and the side effects are low.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48539628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-02DOI: 10.30683/1929-2279.2020.09.12
C. Krauss, Chelsey Aurelius, Kayla Johnston, Victoria H Bartlette, Sherrita Gavin, Jazmine Cuffee, Satyendra N. Banerjee, Sarah Wiseniewsky, S. Mandal, H. Banerjee
Endometrial cancer of the uterus is highly maslignant with an increase rate of morbidity and mortality in both childbearing age and postmenopausal women. Rhenium compounds have been shown to have therapeutic properties against various cancers both in vitro cell lines and in vivo animal models. In this in vitro study, we investigated the effects of a novel group of Rhenium ligands on a uterine cancer cell line. Our initial results showed that these compounds are cytotoxic, induces apoptosis and prevents tubulin polymerization in these uterine cancer cell lines, we also found these novel Rhenium compounds to be noncytocidal to healthy human blood lymphocyte cells, thus proving their safety and efficacy in future translational studies.
{"title":"An Investigation to Study the Role of Novel Rhenium Compounds on Endometrial Uterine Cancer Cell Lines","authors":"C. Krauss, Chelsey Aurelius, Kayla Johnston, Victoria H Bartlette, Sherrita Gavin, Jazmine Cuffee, Satyendra N. Banerjee, Sarah Wiseniewsky, S. Mandal, H. Banerjee","doi":"10.30683/1929-2279.2020.09.12","DOIUrl":"https://doi.org/10.30683/1929-2279.2020.09.12","url":null,"abstract":"Endometrial cancer of the uterus is highly maslignant with an increase rate of morbidity and mortality in both childbearing age and postmenopausal women. Rhenium compounds have been shown to have therapeutic properties against various cancers both in vitro cell lines and in vivo animal models. In this in vitro study, we investigated the effects of a novel group of Rhenium ligands on a uterine cancer cell line. Our initial results showed that these compounds are cytotoxic, induces apoptosis and prevents tubulin polymerization in these uterine cancer cell lines, we also found these novel Rhenium compounds to be noncytocidal to healthy human blood lymphocyte cells, thus proving their safety and efficacy in future translational studies.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"9 1","pages":"102 - 106"},"PeriodicalIF":0.0,"publicationDate":"2020-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69565150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-18DOI: 10.30683/1929-2279.2020.09.02
S. Gantsev, S. Kzyrgalin, K. Gantsev
Objective: to assess the correlation between microscopically discernible peritumoral lymphangiogenesis and breast carcinoma survival rates; to reveal the regularities of macroscopic changes in the structure of axillary lymphatic system in breast cancer. Materials and Methods: We carried out morphometric examination of axillary tissue complexes that had been taken from 100 women during surgery for breast carcinoma, stage T1-3N1-2M0 and had been treated with sonolipodistruction. The density of realized lymphatic vessels was determined by counting the number of lymphangiogenesis "points". An anastomosis between individual lymphatic vessels was taken as a "point". Correlation of macroscopically distinguishable peritumoral lymphangiogenesis expression and survival rate was determined using Pearson's parametric analysis. Results: The analysis of lymphatic maps allowed us to reveal some patterns of axillary lymphatic collector reorganization in breast carcinoma and to distinguish the following types: "Sequential", "Magistral", "Uniform", "Radial" and "Reticulate". Based on the results of prospective observation, 16 patients from the observation group died within the period of 5 years. According to the Pearson correlation analysis, the correlation coefficient was 0,87, the determination coefficient was 0,7488, the value of p = 0,000015, which indicates that in the breast carcinoma, stage T1-3 N1-2 M0 there is a statistically significant direct correlation between the number of "points" of macroscopically distinguishable peritumoral lymphangiogenesis and lifespan after a radical surgical treatment. Lymphatic vessels in the process of peritumoral lymphangiogenesis are the indicator of compensatory-protective resources condition.
{"title":"Peritumoral Lymphangiogenesis in Breast Carcinoma","authors":"S. Gantsev, S. Kzyrgalin, K. Gantsev","doi":"10.30683/1929-2279.2020.09.02","DOIUrl":"https://doi.org/10.30683/1929-2279.2020.09.02","url":null,"abstract":"Objective: to assess the correlation between microscopically discernible peritumoral lymphangiogenesis and breast carcinoma survival rates; to reveal the regularities of macroscopic changes in the structure of axillary lymphatic system in breast cancer. Materials and Methods: We carried out morphometric examination of axillary tissue complexes that had been taken from 100 women during surgery for breast carcinoma, stage T1-3N1-2M0 and had been treated with sonolipodistruction. The density of realized lymphatic vessels was determined by counting the number of lymphangiogenesis \"points\". An anastomosis between individual lymphatic vessels was taken as a \"point\". Correlation of macroscopically distinguishable peritumoral lymphangiogenesis expression and survival rate was determined using Pearson's parametric analysis. Results: The analysis of lymphatic maps allowed us to reveal some patterns of axillary lymphatic collector reorganization in breast carcinoma and to distinguish the following types: \"Sequential\", \"Magistral\", \"Uniform\", \"Radial\" and \"Reticulate\". Based on the results of prospective observation, 16 patients from the observation group died within the period of 5 years. According to the Pearson correlation analysis, the correlation coefficient was 0,87, the determination coefficient was 0,7488, the value of p = 0,000015, which indicates that in the breast carcinoma, stage T1-3 N1-2 M0 there is a statistically significant direct correlation between the number of \"points\" of macroscopically distinguishable peritumoral lymphangiogenesis and lifespan after a radical surgical treatment. Lymphatic vessels in the process of peritumoral lymphangiogenesis are the indicator of compensatory-protective resources condition.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47271831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-11DOI: 10.30683/1929-2279.2020.09.10
J. Yao, Mengjie Zhao, Jiang-An Wang, Liuya Wei
Acute myeloid leukemia (AML) is a clinical and genetic heterogeneous disease with a poor prognosis. Recent advances in genomics and molecular biology have immensely improved the understanding of disease. The advantages of syndrome differentiation and treatment are strong selectivity, good curative effect and lesser side effects. In recent years, according to the molecular mechanism of acute myeloid leukemia, many new therapeutic targets have been found. New targets of differentiation therapy in recent years, such as cell cyclin-dependent kinase (CDK2), isocitrate dehydrogenase (IDH1, IDH2), Homeobox genes (HoxA9), Dihy-droorotate dehydrogenase (DHODH) and some others, are reviewed in this article.
{"title":"Advances in New Targets for Differentiation Therapy of Acute Myeloid Leukemia","authors":"J. Yao, Mengjie Zhao, Jiang-An Wang, Liuya Wei","doi":"10.30683/1929-2279.2020.09.10","DOIUrl":"https://doi.org/10.30683/1929-2279.2020.09.10","url":null,"abstract":"Acute myeloid leukemia (AML) is a clinical and genetic heterogeneous disease with a poor prognosis. Recent advances in genomics and molecular biology have immensely improved the understanding of disease. The advantages of syndrome differentiation and treatment are strong selectivity, good curative effect and lesser side effects. In recent years, according to the molecular mechanism of acute myeloid leukemia, many new therapeutic targets have been found. New targets of differentiation therapy in recent years, such as cell cyclin-dependent kinase (CDK2), isocitrate dehydrogenase (IDH1, IDH2), Homeobox genes (HoxA9), Dihy-droorotate dehydrogenase (DHODH) and some others, are reviewed in this article.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48496369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher Krauss, Chelsey Aurelius, Kayla Johnston, Victoria Bartlette, Sherrita Gavin, Jazmine Cuffee, Satyendra Banerjee, Sarah Wiseniewsky, Santosh Mandal, Hirendra Nath Banerjee
Endometrial cancer of the uterus is highly maslignant with an increase rate of morbidity and mortality in both childbearing age and postmenopausal women. Rhenium compounds have been shown to have therapeutic properties against various cancers both in vitro cell lines and in vivo animal models. In this in vitro study, we investigated the effects of a novel group of Rhenium ligands on a uterine cancer cell line. Our initial results showed that these compounds are cytotoxic, induces apoptosis and prevents tubulin polymerization in these uterine cancer cell lines, we also found these novel Rhenium compounds to be noncytocidal to healthy human blood lymphocyte cells, thus proving their safety and efficacy in future translational studies.
{"title":"An Investigation to Study the Role of Novel Rhenium Compounds on Endometrial Uterine Cancer Cell Lines.","authors":"Christopher Krauss, Chelsey Aurelius, Kayla Johnston, Victoria Bartlette, Sherrita Gavin, Jazmine Cuffee, Satyendra Banerjee, Sarah Wiseniewsky, Santosh Mandal, Hirendra Nath Banerjee","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Endometrial cancer of the uterus is highly maslignant with an increase rate of morbidity and mortality in both childbearing age and postmenopausal women. Rhenium compounds have been shown to have therapeutic properties against various cancers both <i>in vitro</i> cell lines and <i>in vivo</i> animal models. In this <i>in vitro</i> study, we investigated the effects of a novel group of Rhenium ligands on a uterine cancer cell line. Our initial results showed that these compounds are cytotoxic, induces apoptosis and prevents tubulin polymerization in these uterine cancer cell lines, we also found these novel Rhenium compounds to be noncytocidal to healthy human blood lymphocyte cells, thus proving their safety and efficacy in future translational studies.</p>","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"9 ","pages":"102-106"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/30/nihms-1699010.PMC8336948.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39280518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.30683/1929-2279.2019.08.06
K. Akinwumi
: Di-2-ethylhexyl phthalate (DEHP) is a ubiquitous environmental toxicant with high exposure potential to man mainly through leaching from water and foods plastics packages. Exposure to DEHP is associated with cancers, cardiovascular diseases, and splenic toxicity. In the present study, the effect of alpha tocopherol ( α - tocopherol) on the DEHP- induced alteration in hematology and oxidative injury in the spleen of male Sprague Dawley rats was investigated. Animals were exposed daily for six weeks to 5 mg/kg bd.wt DEHP and 10 mg/kg bd.wt Vitamin E either alone or in combination. Control rats were given olive oil throughout the duration of the experiment. Organ weight indices and hematology parameters including packed cell volume (PCV), white blood cells (WBC), lymphocytes and neutrophils were determined in test and control rats. In addition, malondialdehyde, superoxide dismustase (SOD), catalase and glutathione-S-transferase (GST) activities were determined in the spleen. Histology of the spleen was also evaluated. Hematoxicity of DHEP was characterized by decreased PCV, WBC counts and neutrophil, while eosinophil was markedly elevated. DHEP administration resulted in oxidative stress that was manifested by elevated MDA and GST coupled with decreases in SOD and catalase activities. The spleen sections from DEHP-treated rats showed congestion and hyperplasia. However, Vitamin E modulated the hematological parameters and alleviated oxidative changes caused by DEHP exposure. Vitamin E also prevented DHEP associated lesions in the spleen. Therefore, Vitamin E could be useful in controlling hematotoxicty and splenic oxidative injury caused by DEHP intoxication.
{"title":"Vitamin E Alleviates Diethylhexyl Phthalate-Induced Haemato-logical Changes and Splenic Oxidative Injury in Male Sprague-Dawley Rats","authors":"K. Akinwumi","doi":"10.30683/1929-2279.2019.08.06","DOIUrl":"https://doi.org/10.30683/1929-2279.2019.08.06","url":null,"abstract":": Di-2-ethylhexyl phthalate (DEHP) is a ubiquitous environmental toxicant with high exposure potential to man mainly through leaching from water and foods plastics packages. Exposure to DEHP is associated with cancers, cardiovascular diseases, and splenic toxicity. In the present study, the effect of alpha tocopherol ( α - tocopherol) on the DEHP- induced alteration in hematology and oxidative injury in the spleen of male Sprague Dawley rats was investigated. Animals were exposed daily for six weeks to 5 mg/kg bd.wt DEHP and 10 mg/kg bd.wt Vitamin E either alone or in combination. Control rats were given olive oil throughout the duration of the experiment. Organ weight indices and hematology parameters including packed cell volume (PCV), white blood cells (WBC), lymphocytes and neutrophils were determined in test and control rats. In addition, malondialdehyde, superoxide dismustase (SOD), catalase and glutathione-S-transferase (GST) activities were determined in the spleen. Histology of the spleen was also evaluated. Hematoxicity of DHEP was characterized by decreased PCV, WBC counts and neutrophil, while eosinophil was markedly elevated. DHEP administration resulted in oxidative stress that was manifested by elevated MDA and GST coupled with decreases in SOD and catalase activities. The spleen sections from DEHP-treated rats showed congestion and hyperplasia. However, Vitamin E modulated the hematological parameters and alleviated oxidative changes caused by DEHP exposure. Vitamin E also prevented DHEP associated lesions in the spleen. Therefore, Vitamin E could be useful in controlling hematotoxicty and splenic oxidative injury caused by DEHP intoxication.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45004239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.30683/1929-2279.2019.08.07
Khosravi-Shahi Parham
: Background : Liver abscesses are uncommon, but they are associated with a hospital mortality rate of 10% in patients without cancer. However, its relevance in cancer patients in terms of survival and length of hospitalization is unknown. Patients and Methods : We conducted an observational study in order to analyze the impact of liver abscesses in hospitalized cancer patients. Eligible patients were adults with a solid tumor, received antineoplastic treatment and were hospitalized in our department with a diagnosis of liver abscesses. Primary end-points of the study were overall survival (OS) and mean hospital stay (MHS). Secondary end-points were the description of risk factors of liver abscesses, isolated microorganisms and the specific treatment. Results : In our study the incidence of liver abscesses in cancer patients was 1.18%. Median age was 63 years, 60% were men, and the vast majority of patients had an advanced bilio-pancreatic tumor (85%). With a median follow-up of 18 months, median OS was 6 months (95% CI: 1-11); and OS probability at 18-month was 19%. MHS was 27.2 days (95% CI: 20.3-40.7). Risk factors for developing liver abscesses were: a) bilio-pancreatic cancers; b) chemotherapy administration; c) severe malnutrition; and d) biliary drainage/prosthesis. Ten patients (50%) had bacteremia, and the most common isolated microorganism was E.coli (30%). Percutaneous drainage of abscesses was performed in 40% of the patients, and all patients were treated with broad-spectrum antibiotics. Conclusions : Although liver abscesses were uncommon, they were associated with a prolonged hospitalization and poor outcome in cancer patients.
{"title":"Liver Abscesses in Cancer Patients Associated with Poor Prognosis: A Single Center Experience","authors":"Khosravi-Shahi Parham","doi":"10.30683/1929-2279.2019.08.07","DOIUrl":"https://doi.org/10.30683/1929-2279.2019.08.07","url":null,"abstract":": Background : Liver abscesses are uncommon, but they are associated with a hospital mortality rate of 10% in patients without cancer. However, its relevance in cancer patients in terms of survival and length of hospitalization is unknown. Patients and Methods : We conducted an observational study in order to analyze the impact of liver abscesses in hospitalized cancer patients. Eligible patients were adults with a solid tumor, received antineoplastic treatment and were hospitalized in our department with a diagnosis of liver abscesses. Primary end-points of the study were overall survival (OS) and mean hospital stay (MHS). Secondary end-points were the description of risk factors of liver abscesses, isolated microorganisms and the specific treatment. Results : In our study the incidence of liver abscesses in cancer patients was 1.18%. Median age was 63 years, 60% were men, and the vast majority of patients had an advanced bilio-pancreatic tumor (85%). With a median follow-up of 18 months, median OS was 6 months (95% CI: 1-11); and OS probability at 18-month was 19%. MHS was 27.2 days (95% CI: 20.3-40.7). Risk factors for developing liver abscesses were: a) bilio-pancreatic cancers; b) chemotherapy administration; c) severe malnutrition; and d) biliary drainage/prosthesis. Ten patients (50%) had bacteremia, and the most common isolated microorganism was E.coli (30%). Percutaneous drainage of abscesses was performed in 40% of the patients, and all patients were treated with broad-spectrum antibiotics. Conclusions : Although liver abscesses were uncommon, they were associated with a prolonged hospitalization and poor outcome in cancer patients.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41846284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.30683/1929-2279.2019.08.08
G. Capella
: Do "Clinically Insignificant, HIstological MElanoma-Like Lesions" (CIHIMELL) – to wit, merely incidental, looking-like-melanoma lesions devoid of intrinsic malignant potential - exist? The question arises from the fact that, in spite of increased diagnoses of completely excised malignant melanoma (MM) in the last two decades, mortality from advanced metastatic disease has not decreased. After a brief review of the literature, the author proposes that the existence of CIHIMELL could be affirmed through post mortem dermoscopy and histological study of any pigmented lesion, clinically or dermoscopically suspected, of several deceased patients undergoing necropsy for death causes unrelated to MM. Should the cumulative prevalence of merely histological melanomas turn out to be exceedingly high and not commensurable with the current death rates of true MM, the discrepancy would tangibly prove that indolent pigmented lesions with morphological aspect of melanoma do exist. This would clearly introduce difficulties that could satisfactorily be dealt with only through a paradigm shift in melanoma surveillance and diagnosis (which could also allow to add a piece of “encouraging uncertainty” to the patient-physician relationship). However, it can be expected that such an enterprise would be countered by several vested academic and commercial interests.
{"title":"Do \"Incidental Melanomas\" Exist? If so, how many are they? High Time to Decide","authors":"G. Capella","doi":"10.30683/1929-2279.2019.08.08","DOIUrl":"https://doi.org/10.30683/1929-2279.2019.08.08","url":null,"abstract":": Do \"Clinically Insignificant, HIstological MElanoma-Like Lesions\" (CIHIMELL) – to wit, merely incidental, looking-like-melanoma lesions devoid of intrinsic malignant potential - exist? The question arises from the fact that, in spite of increased diagnoses of completely excised malignant melanoma (MM) in the last two decades, mortality from advanced metastatic disease has not decreased. After a brief review of the literature, the author proposes that the existence of CIHIMELL could be affirmed through post mortem dermoscopy and histological study of any pigmented lesion, clinically or dermoscopically suspected, of several deceased patients undergoing necropsy for death causes unrelated to MM. Should the cumulative prevalence of merely histological melanomas turn out to be exceedingly high and not commensurable with the current death rates of true MM, the discrepancy would tangibly prove that indolent pigmented lesions with morphological aspect of melanoma do exist. This would clearly introduce difficulties that could satisfactorily be dealt with only through a paradigm shift in melanoma surveillance and diagnosis (which could also allow to add a piece of “encouraging uncertainty” to the patient-physician relationship). However, it can be expected that such an enterprise would be countered by several vested academic and commercial interests.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45366961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.30683/1929-2279.2019.08.01
Irene Ruiz
Although histologically invasive breast carcinomas can be of no special subtype (ductal) or of special subtypes (as lobular carcinoma), based on their immunohistochemical and molecular features, they are subclassified in four different groups: luminal A, luminal B (with and without HER2 overexpression), HER2 subtype and triple negative. They vary in their gene expression signature, biological potential and clinical course. Luminal A subtype is considered to have a better prognosis and most are treated with hormone therapy alone after surgery because they express hormone receptors and show a low proliferation index. Oncotype DX (ODX) is a molecular score assay that estimates recurrence risk for early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It can predict which tumours may benefit from adjuvant chemotherapy. It has been reported that occasionally a breast carcinoma can have immunohistochemical and molecular differences between the in situ and the invasive components. We report one case that may lead us to misinterpret ODX results, where the in situ ductal component amplified HER2 gene while invasive component did not. Therefore, carefulness must be taken when evaluating ODX results, and be sure that we are evaluating the invasive component.
{"title":"HER2 Expression Discordance between Ductal Carcinoma In situ and Invasive Breast Carcinoma. How to Analyze Oncotype DX","authors":"Irene Ruiz","doi":"10.30683/1929-2279.2019.08.01","DOIUrl":"https://doi.org/10.30683/1929-2279.2019.08.01","url":null,"abstract":"Although histologically invasive breast carcinomas can be of no special subtype (ductal) or of special subtypes (as lobular carcinoma), based on their immunohistochemical and molecular features, they are subclassified in four different groups: luminal A, luminal B (with and without HER2 overexpression), HER2 subtype and triple negative. They vary in their gene expression signature, biological potential and clinical course. Luminal A subtype is considered to have a better prognosis and most are treated with hormone therapy alone after surgery because they express hormone receptors and show a low proliferation index. Oncotype DX (ODX) is a molecular score assay that estimates recurrence risk for early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It can predict which tumours may benefit from adjuvant chemotherapy. It has been reported that occasionally a breast carcinoma can have immunohistochemical and molecular differences between the in situ and the invasive components. We report one case that may lead us to misinterpret ODX results, where the in situ ductal component amplified HER2 gene while invasive component did not. Therefore, carefulness must be taken when evaluating ODX results, and be sure that we are evaluating the invasive component.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42662917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：